Table 5.
Pharmacokinetic parameters of CorA and CorA formulations after IV administration of a CorA-solution (36 mg/kg) and PO administration of the solid CorA-ASD formulations CorA-povidone and CorA copovidone (36 mg/kg) in female BALB/c mice (median ± IQR, n = 4 per group).
| AUC0–inf (µg·h/mL) |
Cmax
(µg/mL) |
Tmax (min) |
BA (%) |
|
|---|---|---|---|---|
| Reference of CorA–IV # | 127.7 (110.2–149.0) |
119.6 (103.7–136.7) |
5 * | 100 ** |
| Neat CorA | 4.5 (3.8–7.4) |
0.9 (0.6–1.1) |
60 (53–90) |
3 |
| CorA-povidone | 41.9 (39.6–46.5) |
33.2 (30.3–37.9) |
15 (10–15) |
33 |
| CorA-copovidone | 13.4 (11.4–17.4) |
5.0 (3.0–7.4) |
30 (30–38) |
10 |
* First measured value; ** IV result median set to 100%; # [14].